Oestrogens and Oestrogen Receptors in Prostate Cancer

Overview

Journal Springerplus

Date 2016 May 18

PMID 27186486

Citations 10

Authors

Karolina Kowalska

Agnieszka Wanda Piastowska-Ciesielska

Affiliations

Soon will be listed here.

Abstract

The role of androgens in prostate cancer is obvious due to the fact that androgen signalling is the main regulator of prostate growth and function. Androgen deprivation therapy is a mainstay treatment for advanced prostate cancer. However, prostate cancer often becomes androgen-independent, which in consequence leads to lethal and incurable disease. In addition, oestrogens play a crucial role in prostate cancer, especially in elder men in whom the overall ratio of oestrogens to androgens is increasing. This review summarizes the current knowledge on molecular mechanisms through which oestrogens are involved in prostate cancer development. We focused on commonly alternated molecular signalling pathways contributing to tumourgenesis in prostate cancer.

Citing Articles

The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.

Figueira M, Carvalho T, Macario-Monteiro J, Cardoso H, Correia S, Vaz C Biomedicines. 2024; 12(8).

PMID: 39200101 PMC: 11351860. DOI: 10.3390/biomedicines12081636.

Lifelong exercise training promotes the remodelling of the immune system and prostate signalome in a rat model of prostate carcinogenesis.

Nascimento-Goncalves E, Seixas F, Palmeira C, Martins G, Fonseca C, Duarte J Geroscience. 2023; 46(1):817-840.

PMID: 37171559 PMC: 10828357. DOI: 10.1007/s11357-023-00806-5.

Estrogen receptors regulate galectin‑3 in androgen‑independent DU‑145 prostate cancer cells.

Souza D, Macheroni C, Vicente C, Cavalheiro R, Campo V, Porto C Oncol Rep. 2023; 49(5).

PMID: 36960864 PMC: 10086566. DOI: 10.3892/or.2023.8530.

Molecular Mechanism of Tanshinone against Prostate Cancer.

Li W, Huang T, Xu S, Che B, Yu Y, Zhang W Molecules. 2022; 27(17).

PMID: 36080361 PMC: 9457553. DOI: 10.3390/molecules27175594.

Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases.

Bozovic A, Mandusic V, Todorovic L, Krajnovic M Int J Mol Sci. 2021; 22(4).

PMID: 33562134 PMC: 7914503. DOI: 10.3390/ijms22041656.

References

Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M . Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate. 2009; 69(11):1245-55. DOI: 10.1002/pros.20966. View

Leung Y, Lam H, Wu S, Song D, Levin L, Cheng L . Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocr Relat Cancer. 2010; 17(3):675-89. PMC: 2891483. DOI: 10.1677/ERC-09-0294. View

Bishop J, Davies A, Ketola K, Zoubeidi A . Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. Endocr Relat Cancer. 2015; 22(3):R165-82. DOI: 10.1530/ERC-15-0137. View

Christoforou P, Christopoulos P, Koutsilieris M . The role of estrogen receptor β in prostate cancer. Mol Med. 2014; 20:427-34. PMC: 4212017. DOI: 10.2119/molmed.2014.00105. View

Nelson A, Tilley W, Neal D, Carroll J . Estrogen receptor beta in prostate cancer: friend or foe?. Endocr Relat Cancer. 2014; 21(4):T219-34. DOI: 10.1530/ERC-13-0508. View

Kanagaraj P, Vijayababu M, Ilangovan R, Senthilkumar K, Venkataraman P, Aruldhas M . Effect of 17beta-estradiol on apoptosis, IGF system components and gelatinases A and B in prostate cancer cells (PC-3). Clin Chim Acta. 2006; 377(1-2):70-8. DOI: 10.1016/j.cca.2006.07.030. View

Yun H, Xie J, Olumi A, Ghosh R, Kumar A . Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity. Oncotarget. 2015; 6(13):11600-13. PMC: 4484479. DOI: 10.18632/oncotarget.3417. View

Corey E, Quinn J, Emond M, Buhler K, Brown L, Vessella R . Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res. 2002; 8(4):1003-7. View

Stein M, Goodin S, Doyle-Lindrud S, Silberberg J, Kane M, Metzger D . Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit. 2012; 18(4):CR260-4. PMC: 3560819. DOI: 10.12659/msm.882626. View

10.

Nakamura Y, Felizola S, Kurotaki Y, Fujishima F, McNamara K, Suzuki T . Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERβ) in human prostate cancer. Prostate. 2012; 73(6):590-5. DOI: 10.1002/pros.22599. View

11.

Yang M, Wang J, Wang L, Shen C, Su B, Qi M . Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. Prostate. 2015; 75(13):1363-75. DOI: 10.1002/pros.23017. View

12.

Harrison M, Hahn N, Pili R, Oh W, Hammers H, Sweeney C . A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2010; 29(6):1465-74. PMC: 3042040. DOI: 10.1007/s10637-010-9455-x. View

13.

Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R . Diethylstilbestrol in castration-resistant prostate cancer. BJU Int. 2012; 110(11 Pt B):E727-35. DOI: 10.1111/j.1464-410X.2012.11546.x. View

14.

Takizawa I, Lawrence M, Balanathan P, Rebello R, Pearson H, Garg E . Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget. 2014; 6(2):604-16. PMC: 4359242. DOI: 10.18632/oncotarget.2820. View

15.

Valle A, Oliver J, Roca P . Role of uncoupling proteins in cancer. Cancers (Basel). 2013; 2(2):567-91. PMC: 3835092. DOI: 10.3390/cancers2020567. View

16.

Dong P, Jiang L, Liu J, Wu Z, Guo S, Zhang Z . Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling. PLoS One. 2013; 8(12):e83519. PMC: 3871534. DOI: 10.1371/journal.pone.0083519. View

17.

Cheng J, Lee E, Madison L, Lazennec G . Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 2004; 566(1-3):169-72. DOI: 10.1016/j.febslet.2004.04.025. View

18.

Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J . Estrogen receptors: how do they signal and what are their targets. Physiol Rev. 2007; 87(3):905-31. DOI: 10.1152/physrev.00026.2006. View

19.

Hurtado A, Pinos T, Barbosa-Desongles A, Lopez-Aviles S, Barquinero J, Petriz J . Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells. Cell Oncol. 2008; 30(4):349-65. PMC: 4618967. DOI: 10.3233/clo-2008-0430. View

20.

Dey P, Strom A, Gustafsson J . Estrogen receptor β upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene. 2013; 33(33):4213-25. DOI: 10.1038/onc.2013.384. View